Clin2
NCT06522828Possibly a fitRecruiting

Study of SSGJ-707 for advanced gynecologic cancers

Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

Treatments studied

Part of Cancer, Women’s health & pregnancy clinical trials.

This trial tests a new drug called SSGJ-707 for people with advanced endometrial cancer or ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it can help shrink or slow down the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
80 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have advanced endometrial cancer or ovarian cancer that is resistant to platinum chemotherapy.
  • You are able to take care of yourself (ECOG score 0 or 1).
  • Your doctor expects you to live at least 3 months more.
  • You do not have serious side effects left from previous cancer treatments (except hair loss or tiredness).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06390774Recruiting· Phase 1
Study of SSGJ-705 for advanced cancers

This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.

Jinan, Shandong
NCT07016490Recruiting· Phase 1
Study of SSGJ-709 for advanced solid tumors

This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.

Adelaide
NCT07171606Recruiting· Phase 2
Study of a new drug for advanced lung cancer

This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.

Shanghai
NCT07022002Recruiting· Phase 2
Testing a new drug for HER2-positive advanced cancers

This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.

Hangzhou, Zhejiang
NCT06493760Recruiting· Phase 2
Testing a new drug for advanced colorectal cancer

This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.

Shanghai, Shanghai Municipality
NCT07233850Not yet recruiting· Phase 2
SSGJ-706 combination for advanced GI cancers

This trial tests a new drug, SSGJ-706, combined with other treatments for advanced stomach, colon, pancreatic, or esophageal cancer that cannot be removed by surgery. It's for people who have not had prior treatment for their advanced cancer.

Wuhan, Hubei

Hear when a new Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.